Accumulating evidence has shown that abnormal expression of CD44 contributes to cancer progression and metastasis, including ovarian cancer, breast cancer, lung adenocarcinoma, glioblastoma, and colorectal cancer. Here, CD44 is linked to breast carcinoma.